Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONE study of pemafibrate added to SGLT2 inhibitor-based therapy in NAFLD with hypertriglyceridemia and type 2 diabetes
jRCTs061230071Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pemafibrate in metabolic dysfunction-associated steatotic liver disease (MASLD), hypertriglyceridemia and type 2 diabetes mellitus (T2DM), sponsored by Kowa Company, Ltd. Primary endpoint: ALT normalization rate at 24 weeks. Started Dec 2023; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hypertriglyceridemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs061230071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061230071.